QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
NASDAQ:GOVX

GeoVax Labs (GOVX) Stock Forecast, Price & News

$0.57
+0.05 (+9.69%)
(As of 10/2/2023 ET)
Compare
Today's Range
$0.52
$0.60
50-Day Range
$0.51
$0.62
52-Week Range
$0.51
$1.39
Volume
1.07 million shs
Average Volume
838,122 shs
Market Capitalization
$14.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

GeoVax Labs MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
783.4% Upside
$5.00 Price Target
Short Interest
Healthy
2.56% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.83mentions of GeoVax Labs in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$30,219 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.64) to ($0.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.54 out of 5 stars

Medical Sector

154th out of 975 stocks

Pharmaceutical Preparations Industry

51st out of 453 stocks


GOVX stock logo

About GeoVax Labs (NASDAQ:GOVX) Stock

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

GOVX Price History

GOVX Stock News Headlines

GeoVax Labs Secures License Agreement With ProBioGen
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
GeoVax Labs (GOVX) Gets a Buy from Noble Financial
GeoVax Announces Issuance of Ebola Vaccine Patent
GeoVax to Participate in Upcoming Industry Meetings
Geovax Labs: Q1 Earnings Insights
See More Headlines
Receive GOVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GeoVax Labs and its competitors with MarketBeat's FREE daily newsletter.

GOVX Company Calendar

Last Earnings
8/09/2023
Today
10/02/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GOVX
Employees
14
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+802.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-14,020,000.00
Pretax Margin
-1,931,699.75%

Debt

Sales & Book Value

Annual Sales
$80,000.00
Book Value
$1.01 per share

Miscellaneous

Free Float
25,386,000
Market Cap
$14.65 million
Optionable
Not Optionable
Beta
2.87
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. David Alan Dodd (Age 73)
    Chairman, Pres & CEO
    Comp: $469.01k
  • Mr. Mark W. Reynolds CPA (Age 61)
    CPA, CFO & Corp. Sec.
    Comp: $348.2k
  • Dr. Mark J. Newman Ph.D. (Age 68)
    Chief Scientific Officer
    Comp: $364.17k
  • Dr. Harriet Latham Robinson Ph.D. (Age 85)
    Founder & Member of Scientific Advisory Board
  • Dr. Kelly T. McKee Jr. (Age 73)
    M.D., M.P.H., Chief Medical Officer
  • Jeffrey Welch
    Head of Process Devel. & Manufacturing Operations
  • Dr. John W. Sharkey Ph.D. (Age 67)
    VP of Bus. Devel.













GOVX Stock - Frequently Asked Questions

Should I buy or sell GeoVax Labs stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GeoVax Labs in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GOVX shares.
View GOVX analyst ratings
or view top-rated stocks.

What is GeoVax Labs' stock price forecast for 2023?

2 brokerages have issued 12 month price targets for GeoVax Labs' shares. Their GOVX share price forecasts range from $3.00 to $8.00. On average, they expect the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 802.4% from the stock's current price.
View analysts price targets for GOVX
or view top-rated stocks among Wall Street analysts.

How have GOVX shares performed in 2023?

GeoVax Labs' stock was trading at $0.6302 at the beginning of the year. Since then, GOVX shares have decreased by 12.1% and is now trading at $0.5541.
View the best growth stocks for 2023 here
.

Are investors shorting GeoVax Labs?

GeoVax Labs saw a decline in short interest in the month of September. As of September 15th, there was short interest totaling 676,300 shares, a decline of 14.9% from the August 31st total of 794,700 shares. Based on an average daily trading volume, of 345,200 shares, the short-interest ratio is presently 2.0 days.
View GeoVax Labs' Short Interest
.

When is GeoVax Labs' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our GOVX earnings forecast
.

How were GeoVax Labs' earnings last quarter?

GeoVax Labs, Inc. (NASDAQ:GOVX) released its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.06.

What is GeoVax Labs' stock symbol?

GeoVax Labs trades on the NASDAQ under the ticker symbol "GOVX."

How do I buy shares of GeoVax Labs?

Shares of GOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GeoVax Labs' stock price today?

One share of GOVX stock can currently be purchased for approximately $0.55.

How much money does GeoVax Labs make?

GeoVax Labs (NASDAQ:GOVX) has a market capitalization of $14.65 million and generates $80,000.00 in revenue each year. The company earns $-14,020,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.

How can I contact GeoVax Labs?

GeoVax Labs' mailing address is 1900 LAKE PARK DRIVE SUITE 380, SMYRNA GA, 30080. The official website for the company is www.geovax.com. The company can be reached via phone at (678) 384-7220, via email at investor@geovax.com, or via fax at 678-384-7281.

This page (NASDAQ:GOVX) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -